The Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer held in 2001 at St. Gallen, Switzerland, recommended therapy for women with operable breast cancer.
Parameters:
(1) node status (positive or negative)
(2) risk group if node negative
(3) endocrine responsiveness
(4) menopausal status
If the tumor was endocrine unresponsive, then chemotherapy is given for all patients.
Premenopausal Woman
Risk Group
Therapeutic Recommendation
node negative, minimal/low risk
none, or tamoxifen
node negative, average/high risk
ovarian ablation + tamoxifen +/- chemotherapy
ovarian ablation
tamoxifen + chemotherapy
tamoxifen
node positive
ovarian ablation + tamoxifen +/- chemotherapy
tamoxifen + chemotherapy
where:
• Ovarian ablation may be permanent (surgical) or for a limited period using a gonadotropin-releasing hormone (GnRH) analog.
• Chemotherapeutic regimens are discussed on pages 3821 and 3822.
Postmenopausal Woman
Risk Group
Therapeutic Recommendation
node negative, minimal/low risk
none, or tamoxifen
node negative, average/high risk
tamoxifen with or without chemotherapy
node positive
chemotherapy with or without tamoxifen
To read more or access our algorithms and calculators, please log in or register.
